Pfizer Inc (PFE) 32.77 $PFE
Argos Therapeutics Falls on Disappointing Phase IIb HIV Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 18 mins ago
Argos Therapeutics Inc.'s (ARGS) AGS-004 failed to meet the primary endpoint in a phase IIb study for the treatment of patients suffering from chronic HIV-1 infection.
ARGS: 7.71 (+1.20), PFE: 32.77 (+0.12), ALXN: 183.36 (-0.91), RGDO: 0.90 (-0.02)
Most active New York Stock Exchange-traded stocks
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
FRO: 4.63 (+0.69), GE: 23.98 (-0.05), AA: 16.17 (+0.06), ABX.TO: 13.58 (+0.54), ABX: 11.33 (+0.34), PFE: 32.77 (+0.12), C: 50.38 (-0.40), HAL: 38.54 (-1.26), BAC: 16.68 (-0.30), AKS: 4.65 (-0.75), TWTR: 39.37 (-0.80)
Midday Glance: Pharmaceuticals companies
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 104.58 (-0.36), BAX: 72.72 (+0.34), PFE: 32.77 (+0.12), BMY: 62.18 (+1.86)
Early Glance: Pharmaceuticals companies
AP - Mon Jan 12, 9:45AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 104.58 (-0.36), BAX: 72.72 (+0.34), PFE: 32.77 (+0.12), BMY: 62.18 (+1.86)
23andMe Announces Collaboration with Pfizer Inc. to Conduct Genetic Research Through 23andMe's Research Platform
PR Newswire - Mon Jan 12, 8:00AM CST
23andMe, Inc., the leading personal genetics company, today announced an agreement with Pfizer Inc. that will provide Pfizer with access to 23andMe's research platform, including services and Research Portal analysis of 23andMe's genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe's Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company's unique research model while still protecting the privacy and security of 23andMe's customers. Researchers can now fully benefit from the largest dataset of its kind, running queries in minutes across more than 1,000 different diseases, conditions and traits. With this information researchers can identify new associations between genes and diseases and traits more quickly than ever before.
PFE: 32.77 (+0.12)
HemoShear Announces Collaboration with Pfizer Inc. To Help Identify and Predict Drug-Induced Vascular Injury for Early Stage Compounds
PR Newswire - Mon Jan 12, 7:00AM CST
HemoShear, a privately held discovery stage biotechnology company, announced today a multi-year platform collaboration with Pfizer Inc. Under the terms of the agreement, which will combine the scientific and technical expertise of both companies, HemoShear will leverage its proprietary discovery platform with the aim to develop a predictive model for preclinical drug-induced vascular injury (DIVI). Financial terms of the collaboration were not disclosed.
PFE: 32.77 (+0.12)
Is Celgene Corporation a Takeover Target in 2015?
George Budwell, The Motley Fool - Motley Fool - Mon Jan 12, 6:30AM CST
Source: Celgene. The pharmaceutical industry underwent a major consolidation last year, driven by the loss of former top-selling drugs to the patent cliff, huge cash positions built up over the preceding decade, and an innovation boom that has made...
BLUE: 101.95 (-1.68), GILD: 101.21 (-1.00), PFE: 32.77 (+0.12), GSK: 42.93 (+0.13), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33)
Why Johnson & Johnson Is Cheering on This Small Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 6:02AM CST
Source: Johnson & Johnson Johnson & Johnson is one of the globe's biggest drugmakers, so it may be a bit surprising to learn that J&J has a lot riding on the success of Portola Pharmaceuticals , a small cap biotech company that is...
JNJ: 104.58 (-0.36), PTLA: 28.67 (-1.66), PFE: 32.77 (+0.12), BMY: 62.18 (+1.86)
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Jan 10, 1:07PM CST
Source: Flickr via Idaho National Laboratory. Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage...
BLUE: 101.95 (-1.68), DVAX: 18.58 (+0.87), HTGC: 14.70 (+0.12), NVAX: 6.41 (+0.10), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), CLDN: 18.35 (-0.25), GSK: 42.93 (+0.13)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Final Glance: Pharmaceuticals companies
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 104.58 (-0.36), BAX: 72.72 (+0.34), PFE: 32.77 (+0.12), BMY: 62.18 (+1.86)
Dow 30 Stock Roundup: Pfizer Acquires Redvax, Microsoft Launches Affordable Internet-ready Phone - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Jan 09, 1:48PM CST
The Dow started the week on a poor note before recovering considerably.
JNJ: 104.58 (-0.36), MMM: 160.74 (-0.88), JPM: 58.83 (-0.51), IBM: 156.44 (-2.67), PFE: 32.77 (+0.12), MSFT: 46.60 (-0.59), INTC: 36.60 (-0.16), CVX: 105.88 (-2.33), NOK: 7.52 (-0.03)
3 Pharma Stocks That Soared Past Pfizer in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jan 09, 1:30PM CST
Like many of its pharma counterparts, Pfizer's (PFE) top-line remained under pressure due to generic competition for several products.
PFE: 32.77 (+0.12), AZN: 70.79 (+1.35), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), NVS: 95.48 (-0.64)
2015 Dogs of the Dow: 10 Dividend Stocks You Should Watch This Year
Dan Caplinger, The Motley Fool - Motley Fool - Fri Jan 09, 1:00PM CST
Source: Wikimedia Commons, courtesy Geo Swan. In recent years, investors have discovered the immense value of dividend-paying stocks, which have been one of the few reliable sources of portfolio income in a low-interest-rate environment that has...
KO: 42.64 (-0.39), GE: 23.98 (-0.05), PFE: 32.77 (+0.12), XOM: 90.33 (-1.77), INTC: 36.60 (-0.16), T: 33.49 (+0.09), MRK: 62.30 (-0.26), MCD: 93.01 (-0.20), CAT: 86.89 (-0.76), CVX: 105.88 (-2.33), MSFT: 46.60 (-0.59), VZ: 47.08 (+0.32), CSCO: 28.05 (+0.26)
Does AstraZeneca PLC Stock Offer a Golden Opportunity in 2015?
George Budwell, The Motley Fool - Motley Fool - Fri Jan 09, 10:22AM CST
AstraZeneca PLC was supposed to get absolutely crushed by the loss of patent protection for key products like its acid reflux medication Nexium. Unlike its patent cliff peers, though, AstraZeneca was able to grow its revenue by 4% in the first...
PFE: 32.77 (+0.12), AZN: 70.79 (+1.35)
FDA approves new blood thinner from Japanese drugmaker
AP - Fri Jan 09, 9:38AM CST
WASHINGTON (AP) — The Food and Drug Administration has approved a new blood thinner from a Japanese drugmaker to reduce stroke and blood clots in patients with a common irregular heartbeat.
JNJ: 104.58 (-0.36), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), BMY: 62.18 (+1.86)
Argos Therapeutics Falls on Disappointing Phase IIb HIV Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 18 mins ago
Argos Therapeutics Inc.'s (ARGS) AGS-004 failed to meet the primary endpoint in a phase IIb study for the treatment of patients suffering from chronic HIV-1 infection.
ARGS: 7.71 (+1.20), PFE: 32.77 (+0.12), ALXN: 183.36 (-0.91), RGDO: 0.90 (-0.02)
Most active New York Stock Exchange-traded stocks
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
FRO: 4.63 (+0.69), GE: 23.98 (-0.05), AA: 16.17 (+0.06), ABX.TO: 13.58 (+0.54), ABX: 11.33 (+0.34), PFE: 32.77 (+0.12), C: 50.38 (-0.40), HAL: 38.54 (-1.26), BAC: 16.68 (-0.30), AKS: 4.65 (-0.75), TWTR: 39.37 (-0.80)
Midday Glance: Pharmaceuticals companies
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 104.58 (-0.36), BAX: 72.72 (+0.34), PFE: 32.77 (+0.12), BMY: 62.18 (+1.86)
Early Glance: Pharmaceuticals companies
AP - Mon Jan 12, 9:45AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 104.58 (-0.36), BAX: 72.72 (+0.34), PFE: 32.77 (+0.12), BMY: 62.18 (+1.86)
23andMe Announces Collaboration with Pfizer Inc. to Conduct Genetic Research Through 23andMe's Research Platform
PR Newswire - Mon Jan 12, 8:00AM CST
23andMe, Inc., the leading personal genetics company, today announced an agreement with Pfizer Inc. that will provide Pfizer with access to 23andMe's research platform, including services and Research Portal analysis of 23andMe's genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe's Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company's unique research model while still protecting the privacy and security of 23andMe's customers. Researchers can now fully benefit from the largest dataset of its kind, running queries in minutes across more than 1,000 different diseases, conditions and traits. With this information researchers can identify new associations between genes and diseases and traits more quickly than ever before.
PFE: 32.77 (+0.12)
HemoShear Announces Collaboration with Pfizer Inc. To Help Identify and Predict Drug-Induced Vascular Injury for Early Stage Compounds
PR Newswire - Mon Jan 12, 7:00AM CST
HemoShear, a privately held discovery stage biotechnology company, announced today a multi-year platform collaboration with Pfizer Inc. Under the terms of the agreement, which will combine the scientific and technical expertise of both companies, HemoShear will leverage its proprietary discovery platform with the aim to develop a predictive model for preclinical drug-induced vascular injury (DIVI). Financial terms of the collaboration were not disclosed.
PFE: 32.77 (+0.12)
Is Celgene Corporation a Takeover Target in 2015?
George Budwell, The Motley Fool - Motley Fool - Mon Jan 12, 6:30AM CST
Source: Celgene. The pharmaceutical industry underwent a major consolidation last year, driven by the loss of former top-selling drugs to the patent cliff, huge cash positions built up over the preceding decade, and an innovation boom that has made...
BLUE: 101.95 (-1.68), GILD: 101.21 (-1.00), PFE: 32.77 (+0.12), GSK: 42.93 (+0.13), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33)
Why Johnson & Johnson Is Cheering on This Small Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 6:02AM CST
Source: Johnson & Johnson Johnson & Johnson is one of the globe's biggest drugmakers, so it may be a bit surprising to learn that J&J has a lot riding on the success of Portola Pharmaceuticals , a small cap biotech company that is...
JNJ: 104.58 (-0.36), PTLA: 28.67 (-1.66), PFE: 32.77 (+0.12), BMY: 62.18 (+1.86)
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Jan 10, 1:07PM CST
Source: Flickr via Idaho National Laboratory. Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage...
BLUE: 101.95 (-1.68), DVAX: 18.58 (+0.87), HTGC: 14.70 (+0.12), NVAX: 6.41 (+0.10), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), CLDN: 18.35 (-0.25), GSK: 42.93 (+0.13)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Final Glance: Pharmaceuticals companies
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 104.58 (-0.36), BAX: 72.72 (+0.34), PFE: 32.77 (+0.12), BMY: 62.18 (+1.86)
Dow 30 Stock Roundup: Pfizer Acquires Redvax, Microsoft Launches Affordable Internet-ready Phone - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Jan 09, 1:48PM CST
The Dow started the week on a poor note before recovering considerably.
JNJ: 104.58 (-0.36), MMM: 160.74 (-0.88), JPM: 58.83 (-0.51), IBM: 156.44 (-2.67), PFE: 32.77 (+0.12), MSFT: 46.60 (-0.59), INTC: 36.60 (-0.16), CVX: 105.88 (-2.33), NOK: 7.52 (-0.03)
3 Pharma Stocks That Soared Past Pfizer in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jan 09, 1:30PM CST
Like many of its pharma counterparts, Pfizer's (PFE) top-line remained under pressure due to generic competition for several products.
PFE: 32.77 (+0.12), AZN: 70.79 (+1.35), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), NVS: 95.48 (-0.64)
2015 Dogs of the Dow: 10 Dividend Stocks You Should Watch This Year
Dan Caplinger, The Motley Fool - Motley Fool - Fri Jan 09, 1:00PM CST
Source: Wikimedia Commons, courtesy Geo Swan. In recent years, investors have discovered the immense value of dividend-paying stocks, which have been one of the few reliable sources of portfolio income in a low-interest-rate environment that has...
KO: 42.64 (-0.39), GE: 23.98 (-0.05), PFE: 32.77 (+0.12), XOM: 90.33 (-1.77), INTC: 36.60 (-0.16), T: 33.49 (+0.09), MRK: 62.30 (-0.26), MCD: 93.01 (-0.20), CAT: 86.89 (-0.76), CVX: 105.88 (-2.33), MSFT: 46.60 (-0.59), VZ: 47.08 (+0.32), CSCO: 28.05 (+0.26)
Does AstraZeneca PLC Stock Offer a Golden Opportunity in 2015?
George Budwell, The Motley Fool - Motley Fool - Fri Jan 09, 10:22AM CST
AstraZeneca PLC was supposed to get absolutely crushed by the loss of patent protection for key products like its acid reflux medication Nexium. Unlike its patent cliff peers, though, AstraZeneca was able to grow its revenue by 4% in the first...
PFE: 32.77 (+0.12), AZN: 70.79 (+1.35)
FDA approves new blood thinner from Japanese drugmaker
AP - Fri Jan 09, 9:38AM CST
WASHINGTON (AP) — The Food and Drug Administration has approved a new blood thinner from a Japanese drugmaker to reduce stroke and blood clots in patients with a common irregular heartbeat.
JNJ: 104.58 (-0.36), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), BMY: 62.18 (+1.86)
